SG11201901937WA - Pyridine compound - Google Patents
Pyridine compoundInfo
- Publication number
- SG11201901937WA SG11201901937WA SG11201901937WA SG11201901937WA SG11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA
- Authority
- SG
- Singapore
- Prior art keywords
- chuo
- tokyo
- limited
- international
- honcho
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016191725A JP2018052878A (ja) | 2016-09-29 | 2016-09-29 | ピリジン化合物 |
| PCT/GB2017/052913 WO2018060714A1 (fr) | 2016-09-29 | 2017-09-28 | Composé de pyridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901937WA true SG11201901937WA (en) | 2019-04-29 |
Family
ID=60020249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901937WA SG11201901937WA (en) | 2016-09-29 | 2017-09-28 | Pyridine compound |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10851092B2 (fr) |
| EP (2) | EP3519398B1 (fr) |
| JP (2) | JP2018052878A (fr) |
| KR (1) | KR102520543B1 (fr) |
| CN (2) | CN113788824A (fr) |
| AU (2) | AU2017335242C1 (fr) |
| BR (1) | BR112019006047A2 (fr) |
| CA (1) | CA3035860A1 (fr) |
| CL (1) | CL2019000844A1 (fr) |
| CO (1) | CO2019004034A2 (fr) |
| CY (1) | CY1123988T1 (fr) |
| DK (1) | DK3519398T3 (fr) |
| EA (1) | EA037103B1 (fr) |
| EC (1) | ECSP19030134A (fr) |
| ES (1) | ES2868748T3 (fr) |
| HR (1) | HRP20210447T1 (fr) |
| HU (1) | HUE054824T2 (fr) |
| IL (1) | IL265630B (fr) |
| LT (1) | LT3519398T (fr) |
| MA (2) | MA46337B1 (fr) |
| MD (1) | MD3519398T2 (fr) |
| MX (1) | MX2019003747A (fr) |
| PE (1) | PE20190805A1 (fr) |
| PH (1) | PH12019500480A1 (fr) |
| PL (1) | PL3519398T3 (fr) |
| PT (1) | PT3519398T (fr) |
| RS (1) | RS61640B1 (fr) |
| SG (1) | SG11201901937WA (fr) |
| SI (1) | SI3519398T1 (fr) |
| UA (1) | UA123964C2 (fr) |
| WO (1) | WO2018060714A1 (fr) |
| ZA (1) | ZA201902232B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6807385B2 (ja) | 2015-11-02 | 2021-01-06 | ブループリント メディシンズ コーポレイション | Ｒｅｔの阻害剤 |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| CA3096043A1 (fr) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Inhibiteur de ret destine a etre utilise dans le traitement du cancer presentant une alteration du ret |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (fr) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
| IL293055A (en) * | 2019-11-18 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Ret kinase inhibitors in combination with cyclin-dependent kinase 4 ret/or cyclin-dependent kinase 6 (cdk 4/6) inhibitors for use in cancer treatment |
| CN113121524B (zh) | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| WO2021164741A1 (fr) * | 2020-02-20 | 2021-08-26 | 南京明德新药研发有限公司 | Composé de bisamide de phényle |
| CN115210226B (zh) * | 2020-02-20 | 2024-01-09 | 广州白云山医药集团股份有限公司白云山制药总厂 | 喹啉类化合物 |
| WO2022238706A1 (fr) | 2021-05-14 | 2022-11-17 | Bp Asset Viii, Inc. | Inhibiteur de ret pour le traitement du cancer médullaire de la thyroïde à altération de ret ou du cancer du poumon non à petites cellules à altération de ret |
| AU2022463015A1 (en) | 2021-10-22 | 2024-05-09 | Tract Pharmaceuticals, Inc. | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
| CN115090331B (zh) * | 2022-07-21 | 2023-05-16 | 扬州大学 | 超分子手性催化剂、其制备方法及其催化d-a反应的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| EP1994024A2 (fr) | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Dérivés de la quinoline |
| EP1994023A1 (fr) | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Dérivés de la quinazoline |
| WO2007113565A1 (fr) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Dérivés de la naphtyridine comme agents anti-cancéreux |
| WO2007113548A1 (fr) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Dérivés de naphtyridine |
| FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| CN102333765B (zh) * | 2009-02-27 | 2015-01-14 | 帝人制药株式会社 | 基于使用过渡金属催化剂的偶联法的苯基取代杂环衍生物的制造方法 |
| EP2467137A1 (fr) | 2009-08-19 | 2012-06-27 | Ambit Biosciences Corporation | Composés biaryles et procédés d utilisation de ceux-ci |
| CA2772301A1 (fr) | 2009-08-25 | 2011-03-03 | Abraxis Bioscience, Llc | Pluritherapie avec des compositions nanoparticulaires de taxane et des inhibiteurs hedgehog |
| WO2011133728A2 (fr) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Composés antiviraux |
| US9073895B2 (en) | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| EP2872493B1 (fr) | 2012-07-13 | 2018-11-14 | Indiana University Research and Technology Corporation | 5,6,7-trimethoxy 4-phenyle quinoline-2-ones utilisables en vue du traitement de l'amyotrophie spinale |
| EA029296B1 (ru) * | 2013-03-15 | 2018-03-30 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы |
| EP3039021A1 (fr) * | 2013-08-30 | 2016-07-06 | Ambit Biosciences Corporation | Composés de biaryle acétamide et procédés d'utilisation de ceux-ci |
| GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| TW201623239A (zh) * | 2014-04-24 | 2016-07-01 | 田邊三菱製藥股份有限公司 | 新穎２－胺基－吡啶及２－胺基－嘧啶衍生物及其醫藥用途 |
| JP6538154B2 (ja) * | 2014-09-10 | 2019-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｅｔ（ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ）キナーゼ阻害剤としてのピリジン誘導体 |
| AU2015316438B2 (en) * | 2014-09-10 | 2018-05-24 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds as Rearranged during Transfection (RET) inhibitors |
| WO2016061280A1 (fr) | 2014-10-14 | 2016-04-21 | La Jolla Institute Of Allergy & Immunology | Inhibiteurs de la protéine tyrosine phosphatase de faible poids moléculaire et utilisations |
| CN104844589B (zh) | 2014-12-26 | 2018-04-20 | 中国科学院合肥物质科学研究院 | 一种pi3k激酶抑制剂 |
| US10202365B2 (en) * | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
-
2016
- 2016-09-29 JP JP2016191725A patent/JP2018052878A/ja active Pending
-
2017
- 2017-09-28 KR KR1020197012323A patent/KR102520543B1/ko active IP Right Grant
- 2017-09-28 MD MDE20190863T patent/MD3519398T2/ro unknown
- 2017-09-28 CN CN202111188408.2A patent/CN113788824A/zh active Pending
- 2017-09-28 PL PL17780169T patent/PL3519398T3/pl unknown
- 2017-09-28 HU HUE17780169A patent/HUE054824T2/hu unknown
- 2017-09-28 DK DK17780169.3T patent/DK3519398T3/da active
- 2017-09-28 EP EP17780169.3A patent/EP3519398B1/fr active Active
- 2017-09-28 UA UAA201904549A patent/UA123964C2/uk unknown
- 2017-09-28 EP EP21151210.8A patent/EP3828178A1/fr not_active Withdrawn
- 2017-09-28 CN CN201780074582.XA patent/CN110036007B/zh active Active
- 2017-09-28 AU AU2017335242A patent/AU2017335242C1/en active Active
- 2017-09-28 WO PCT/GB2017/052913 patent/WO2018060714A1/fr unknown
- 2017-09-28 ES ES17780169T patent/ES2868748T3/es active Active
- 2017-09-28 SI SI201730683T patent/SI3519398T1/sl unknown
- 2017-09-28 RS RS20210332A patent/RS61640B1/sr unknown
- 2017-09-28 MA MA46337A patent/MA46337B1/fr unknown
- 2017-09-28 CA CA3035860A patent/CA3035860A1/fr active Pending
- 2017-09-28 LT LTEP17780169.3T patent/LT3519398T/lt unknown
- 2017-09-28 US US16/337,896 patent/US10851092B2/en active Active
- 2017-09-28 BR BR112019006047A patent/BR112019006047A2/pt not_active Application Discontinuation
- 2017-09-28 JP JP2019516670A patent/JP7098609B2/ja active Active
- 2017-09-28 MX MX2019003747A patent/MX2019003747A/es unknown
- 2017-09-28 PT PT177801693T patent/PT3519398T/pt unknown
- 2017-09-28 EA EA201990833A patent/EA037103B1/ru unknown
- 2017-09-28 SG SG11201901937WA patent/SG11201901937WA/en unknown
- 2017-09-28 MA MA054910A patent/MA54910A/fr unknown
- 2017-09-28 PE PE2019000730A patent/PE20190805A1/es unknown
-
2019
- 2019-03-05 PH PH12019500480A patent/PH12019500480A1/en unknown
- 2019-03-26 IL IL265630A patent/IL265630B/en unknown
- 2019-03-28 CL CL2019000844A patent/CL2019000844A1/es unknown
- 2019-04-09 ZA ZA2019/02232A patent/ZA201902232B/en unknown
- 2019-04-23 CO CONC2019/0004034A patent/CO2019004034A2/es unknown
- 2019-04-29 EC ECSENADI201930134A patent/ECSP19030134A/es unknown
-
2020
- 2020-11-24 US US17/103,515 patent/US20210163464A1/en not_active Abandoned
-
2021
- 2021-03-17 CY CY20211100228T patent/CY1123988T1/el unknown
- 2021-03-17 HR HRP20210447TT patent/HRP20210447T1/hr unknown
- 2021-11-03 AU AU2021261899A patent/AU2021261899A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901937WA (en) | Pyridine compound | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201403402VA (en) | Compounds | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| CA2859619C (fr) | Inhibiteurs de bromodomaine | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201809501PA (en) | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |